SOTACOR

This brand name is authorized in Australia, Brazil, Finland, Japan, New Zealand, UK.

Active ingredients

The drug SOTACOR contains one active pharmaceutical ingredient (API):

1	Sotalol UNII HEC37C70XX - SOTALOL HYDROCHLORIDE
	D,l-sotalol is a non-selective hydrophilic β-adrenergic receptor blocking agent, devoid of intrinsic sympathomimetic activity or membrane stabilizing activity. Sotalol has both beta-adrenoreceptor blocking (Vaughan Williams Class II) and cardiac action potential duration prolongation (Vaughan Williams Class III) antiarrhythmic properties.
	Read more about Sotalol

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
SOTACOR Tablet	MPI, EU: SmPC	Medicines & Healthcare Products Regulatory Agency (GB)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
C07AA07	Sotalol	C Cardiovascular system → C07 Beta blocking agents → C07A Beta blocking agents → C07AA Beta blocking agents, non-selective
Discover more medicines within C07AA07

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
AU	Pharmaceutical Benefits Scheme	2043M, 8398B
BR	Câmara de Regulação do Mercado de Medicamentos	505105501118317, 505105502114315
FI	Lääkealan turvallisuus- ja kehittämiskeskus	027938
GB	Medicines & Healthcare Products Regulatory Agency	184856
JP	医薬品医療機器総合機構	2129013F1026, 2129013F2022
NZ	Medicines and Medical Devices Safety Authority	2235, 2236, 2237